Abeona Therapeutics Nears Transformative FDA Decision
AI Prediction of Abeona Therapeutics Inc. Common Stock (ABEO)
Abeona Therapeutics, a clinical-stage biopharmaceutical company, has shown significant progress with its gene therapies and recent positive regulatory developments. With the FDA's acceptance of their BLA for pz-cel and other gene therapies in the pipeline, Abeona is positioned for potential breakthroughs in the treatment of rare genetic diseases. Investors should consider entry prior to anticipated FDA approvals, which could propel the stock upwards.
ABEO Report Information
Prediction Date2025-07-03 06:18:11
Close @ Prediction$5.89
Mkt Cap302m
IPO Date1980-09-19
AI-derived Information
Recent News for ABEO
- Aug 14 — Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 14 — Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
- Aug 11 — Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 | Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
- Aug 1 — Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey)
- Aug 1 — Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Jul 29 — AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
- Jul 15 — ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
- Jul 14 — Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
- Jul 2 — Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire)
- Jul 1 — Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
It seems that ABEO Abeona Therapeutics is getting excellent news, and though a bit late, the stock is on the increase. Currently at $7.20 and we’re looking for imminent breakout and a price as high as $10.